Journal article
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial
- Abstract:
-
Older patients with acute myeloid leukaemia (AML) account for nearly half of those with the disease. Because they are perceived to be unfit for, unwilling to receive, or unlikely to benefit from conventional chemotherapy they represent an important unmet need. Tosedostat is a selective oral aminopeptidase inhibitor, which in phase I/II trials showed acceptable toxicity and encouraging efficacy. We report the only randomised study of low-dose cytosine arabinoside (LDAC) combined with tosedosta...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, 392.1KB, Terms of use)
-
- Publisher copy:
- 10.1111/bjh.17501
Authors
Bibliographic Details
- Publisher:
- Wiley
- Journal:
- British Journal of Haematology More from this journal
- Volume:
- 194
- Issue:
- 2
- Pages:
- 298-308
- Publication date:
- 2021-05-07
- Acceptance date:
- 2021-04-01
- DOI:
- EISSN:
-
1365-2141
- ISSN:
-
0007-1048
- Pmid:
-
33961292
Item Description
- Language:
-
English
- Keywords:
-
- Pubs id:
-
1177963
- Local pid:
-
pubs:1177963
- Deposit date:
-
2022-03-28
Terms of use
- Copyright holder:
- British Society for Haematology and John Wiley & Sons Ltd
- Copyright date:
- 2021
- Rights statement:
- © 2021 British Society for Haematology and John Wiley & Sons Ltd
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Wiley at: https://doi.org/10.1111/bjh.17501
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record